Does Rallies show 13F holders for XRAY?

Yes. Rallies tracks hedge fund and 13F ownership data for XRAY, including fund names, share counts, latest tracked quarter, and position changes when available.

Is XRAY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for XRAY. It does not provide personalized investment advice.

XRAY (DENTSPLY SIRONA Inc.) Stock Analysis - Hedge Fund Holdings

DENTSPLY SIRONA Inc. (XRAY) is a publicly traded Healthcare sector company. As of May 21, 2026, XRAY trades at $9.99 with a market cap of $1.97B and a P/E ratio of 1.92. XRAY moved +1.03% today. Year to date, XRAY is -15.25%; over the trailing twelve months it is -41.11%. Its 52-week range spans $9.41 to $27.44. Analyst consensus is neutral with an average price target of $13.88. Rallies surfaces XRAY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns XRAY stock?

Hedge funds tracked by Rallies that own XRAY include Glenview Capital, Bridgewater Associates, Panagora Asset, Centerbook Partners, and Pinebridge Investments. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for DENTSPLY SIRONA Inc..

XRAY Key Metrics

Key financial metrics for XRAY
Metric	Value
Price	$9.99
Market Cap	$1.97B
P/E Ratio	1.92
EPS	$5.19
Dividend Yield	0.16%
52-Week High	$27.44
52-Week Low	$9.41
Volume	0
Avg Volume	0
Revenue (TTM)	$24.78B
Net Income	$3.69B
Gross Margin	58.94%

Top Hedge Funds Holding XRAY

Glenview Capital holds 855.34K shares of XRAY, changed +0.00% as of Mar 31, 2025.
Bridgewater Associates holds 476.61K shares of XRAY, changed +5.81% as of Dec 31, 2025.
Panagora Asset holds 323.62K shares of XRAY, changed -1.22% as of Mar 31, 2025.
Centerbook Partners holds 69.63K shares of XRAY, changed +0.00% as of Mar 31, 2026.
Pinebridge Investments holds 49.85K shares of XRAY, changed -33.91% as of Sep 30, 2025.

Latest XRAY News

Dentsply Sirona Reports $880M Q1 Sales, 48.5% Gross Margin, Launches AI Diagnostic Tool — May 5, 2026
Dentsply Sirona Expands Southeast CEREC Distribution and Faces Q1 Margin Pressure — May 4, 2026
Dentsply Sirona Debuts FDA-Cleared AI Diagnostic Boosting PARL Detection 46% — May 4, 2026
Dentsply Sirona Unit Rolls Out 24-Hour Surity Male Catheter for 13M U.S. Patients — Apr 30, 2026
FDA Clears First Dental-Dedicated MRI with Under-20-Minute Workflow — Mar 9, 2026

Recent XRAY Insider Trades

LUCIER GREGORY T bought 15.00K (~$186.68K) on Mar 9, 2026.
Forbes James D bought 5.00K (~$62.40K) on Mar 9, 2026.
LUCIER GREGORY T bought 22.45K (~$314.86K) on Mar 3, 2026.

XRAY Analyst Consensus

14 analysts cover XRAY: 0 strong buy, 3 buy, 9 hold, 2 sell, 0 strong sell. Consensus rating is neutral. Average price target: $13.88.

Common questions about XRAY

Who owns XRAY stock?: Hedge funds tracked by Rallies that own XRAY include Glenview Capital, Bridgewater Associates, Panagora Asset, Centerbook Partners, and Pinebridge Investments. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for DENTSPLY SIRONA Inc..
Does Rallies show 13F holders for XRAY?: Yes. Rallies tracks hedge fund and 13F ownership data for XRAY, including fund names, share counts, latest tracked quarter, and position changes when available.
Is XRAY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for XRAY. It does not provide personalized investment advice.